| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2559.2001.01042.X |
| P698 | PubMed publication ID | 11207821 |
| P2093 | author name string | Wells M | |
| Feeley KM | |||
| P433 | issue | 2 | |
| P304 | page(s) | 87-95 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Histopathology | Q1524040 |
| P1476 | title | Precursor lesions of ovarian epithelial malignancy | |
| P478 | volume | 38 |
| Q92336127 | A Comprehensive Review of Ovarian Serous Carcinoma |
| Q36614490 | A distinct molecular profile associated with mucinous epithelial ovarian cancer. |
| Q92036923 | ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo |
| Q36127308 | AXL is an essential factor and therapeutic target for metastatic ovarian cancer |
| Q35084804 | Abdominal pain during pregnancy. |
| Q33953046 | Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response |
| Q35906208 | Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. |
| Q40115732 | Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. |
| Q24684274 | Amplification and Overexpression of the L-MYC Proto-Oncogene in Ovarian Carcinomas |
| Q41994386 | Antimetastatic effects of cordycepin mediated by the inhibition of mitochondrial activity and estrogen-related receptor α in human ovarian carcinoma cells |
| Q38766090 | Aqueous Extract of Paris polyphylla (AEPP) Inhibits Ovarian Cancer via Suppression of Peroxisome Proliferator-Activated Receptor-Gamma Coactivator (PGC)-1alpha. |
| Q33859857 | CA125 in ovarian cancer |
| Q33582300 | Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. |
| Q33739577 | Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. |
| Q59809876 | Cell Origins of High-Grade Serous Ovarian Cancer |
| Q74228508 | Changes in the mouse ovarian surface epithelium with age and ovulation number |
| Q33808368 | Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube. |
| Q37326840 | Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. |
| Q27317427 | Conditional inactivation of p53 in mouse ovarian surface epithelium does not alter MIS driven Smad2-dominant negative epithelium-lined inclusion cysts or teratomas |
| Q36260807 | Coxsackievirus B3 infection reduces female mouse fertility |
| Q53364711 | Cyclooxygenase-2 expression in borderline ovarian tumors. |
| Q49627412 | Developing a deeper insight into reproductive biomarkers |
| Q37324626 | Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery |
| Q38195046 | Development of a mouse model of menopausal ovarian cancer |
| Q34282708 | Development of a syngeneic mouse model of epithelial ovarian cancer |
| Q33858856 | Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion |
| Q42478951 | Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis |
| Q56836339 | Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy |
| Q35221856 | Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background |
| Q36059087 | Do hereditary syndrome-related gynecologic cancers have any specific features? |
| Q52831286 | Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. |
| Q34094731 | Early detection of ovarian cancer |
| Q89855045 | EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance |
| Q39356689 | Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines |
| Q37662367 | Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma |
| Q34249388 | Estrogen and androgen receptor expression in surface epithelium and inclusion cyst in the ovary of premenopausal and postmenopausal women |
| Q36226118 | Evaluation of microsatellite instability in women with epithelial ovarian cancer |
| Q80262379 | Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma |
| Q53664165 | Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. |
| Q38451794 | Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. |
| Q35730185 | Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers |
| Q35843312 | Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma |
| Q43158887 | Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. |
| Q35560963 | Fallopian tube correlates of ovarian serous borderline tumors |
| Q38067435 | Fallopian tube precursors of ovarian low- and high-grade serous neoplasms |
| Q75353680 | Focus on epithelial ovarian cancer |
| Q35683214 | Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells |
| Q37091852 | Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer |
| Q31076542 | Gene expression data analysis in subtypes of ovarian cancer using covariance analysis |
| Q40514008 | Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. |
| Q36446437 | Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization |
| Q53309853 | Genetically engineered mouse models of ovarian cancer and their utility in drug discovery. |
| Q35904590 | Genome-wide significant risk associations for mucinous ovarian carcinoma |
| Q37144104 | Genomic analysis of epithelial ovarian cancer |
| Q35743316 | Genomic complexity and AKT dependence in serous ovarian cancer |
| Q39937614 | Germ cell specific protein VASA is over-expressed in epithelial ovarian cancer and disrupts DNA damage-induced G2 checkpoint |
| Q64080187 | Global epidemiology, risk factors, and histological types of ovarian cancers in Trinidad |
| Q38823190 | HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). |
| Q55045071 | HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. |
| Q36964290 | High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker |
| Q51753726 | High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. |
| Q80277843 | Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma |
| Q90401798 | Identification of a Prognostic Signature Associated With DNA Repair Genes in Ovarian Cancer |
| Q36184966 | Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics |
| Q92442020 | In vivo selection reveals autophagy promotes adaptation of metastatic ovarian cancer cells to abdominal microenvironment |
| Q36496578 | Induction of ovarian cancer by defined multiple genetic changes in a mouse model system |
| Q37200457 | Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells |
| Q38723863 | KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice |
| Q81634756 | Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract |
| Q36784982 | Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific |
| Q36782362 | Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells |
| Q33489525 | Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia |
| Q34247030 | Loss of cables, a novel gene on chromosome 18q, in ovarian cancer |
| Q36855111 | Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis |
| Q38449651 | Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies |
| Q64048290 | Malignant mixed mullerian tumour of the fallopian tube occurring in a patient with Peutz-Jegher's syndrome |
| Q36413347 | Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival |
| Q44332743 | Metaplastic potential of p53 down-regulation in ovarian surface epithelial cells affected by ovulation |
| Q34508726 | Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase |
| Q37741508 | Molecular characterization of ovarian cancer by gene-expression profiling. |
| Q77925411 | Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles |
| Q38456699 | Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity |
| Q34312494 | Molecular genetic analysis of ovarian serous cystadenomas |
| Q35640277 | Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells |
| Q36157106 | Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. |
| Q34586019 | Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma |
| Q82238526 | Ovarian cancer |
| Q35552356 | Ovarian cancer and high-risk women—implications for prevention, screening, and early detection |
| Q36111930 | Ovarian cancer metastasis: integrating insights from disparate model organisms |
| Q24816796 | Ovarian cancer, the coagulation pathway, and inflammation |
| Q37332480 | Ovarian cancer: genomic analysis. |
| Q36466608 | Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma? |
| Q83365155 | Ovarian serous low malignant potential (borderline) tumor--does "micropapillary" matter? |
| Q40162130 | Overexpression of mammaglobin B in epithelial ovarian carcinomas |
| Q37101060 | Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications |
| Q83636948 | Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy |
| Q37760524 | Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. |
| Q35934073 | Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations |
| Q40001879 | Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells |
| Q37480371 | Possible angiogenic roles for claudin-4 in ovarian cancer |
| Q35756907 | Potential for TRAIL as a therapeutic agent in ovarian cancer |
| Q34803840 | Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma |
| Q36564548 | Primary cilia and aberrant cell signaling in epithelial ovarian cancer |
| Q38365195 | Primary peritoneal clear cell carcinoma versus ovarian carcinoma versus malignant transformation of endometriosis: a vexing issue. |
| Q28183254 | Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells |
| Q35061331 | Prognostic relevance of acquired uniparental disomy in serous ovarian cancer |
| Q61855549 | Protein expression patterns associated with advanced stage ovarian cancer |
| Q83414403 | Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers |
| Q37479727 | RETRACTED: Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis |
| Q27009487 | Recent concepts of ovarian carcinogenesis: type I and type II |
| Q24307419 | Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer |
| Q37729974 | Subtypes of Ovarian Cancer and Ovarian Cancer Screening |
| Q41990579 | Systematic module approach identifies altered genes and pathways in four types of ovarian cancer |
| Q35390011 | Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation |
| Q37485865 | Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. |
| Q36510070 | Technical challenges and limitations of current mouse models of ovarian cancer |
| Q33838714 | The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition |
| Q33624201 | The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions |
| Q37740526 | The Role of Endocrine G Protein-Coupled Receptors in Ovarian Cancer Progression. |
| Q36927913 | The Role of microRNAs in the Tumorigenesis of Ovarian Cancer |
| Q33622369 | The biology of ovarian cancer: new opportunities for translation |
| Q34216518 | The blood-follicle barrier (BFB) in disease and in ovarian function |
| Q34654993 | The dominance of the microenvironment in breast and ovarian cancer |
| Q36810356 | The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms |
| Q49219966 | The inhibition of cordycepin on cancer stemness in TGF-beta induced chemo-resistant ovarian cancer cell |
| Q39726998 | The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer |
| Q37385514 | The mammalian ovary from genesis to revelation |
| Q24791520 | The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer |
| Q34029565 | The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation |
| Q39114905 | Thrombomodulin mediates the progression of epithelial ovarian cancer cells |
| Q37726452 | Translational control during early development |
| Q28536689 | Type-specific cell line models for type-specific ovarian cancer research |
| Q63199214 | Wilms Tumor Gene Immunoreactivity in Primary Serous Carcinomas of the Fallopian Tube, Ovary, Endometrium, and Peritoneum |
| Q39432311 | miRNAs and ovarian cancer: An overview |
Search more.